12 April 2024 - Version 2 of the agenda for the July 2024 PBAC meeting is now available; two minor changes.

The minor changes are:

• Faricimab (Vabysmo) - Revised formulation, submission type and submission purpose
• Fruquintinib (Fruzaqla) - Revised formulation (as expected)

Read PBAC agenda